Valbiotis présente les résultats complémentaires positifs
Valbiotis accélère sa stratégie de commercialisation
The European Commission designates OptPA, the W253R/R275S tissue
plasminogen activator developed by Op2Lysis, as an orphan drug for the
treatment of non-traumatic spontaneous intracerebral hemorrhage.
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Coave Therapeutics to Collaborate with World-Renowned Institute of Neurodegenerative Diseases of Bordeaux to Develop Gene Therapy Programs Targeting Protein Degradation in Neurodegenerative Disorders
